Literature DB >> 21466614

Hypoxia-induced β-catenin downregulation involves p53-dependent activation of Siah-1.

Dapeng Wang1, Yongxing Wang, Tao Kong, Feiyue Fan, Yongguang Jiang.   

Abstract

Solid tumors contain extensive hypoxic areas and it is of considerable importance to decipher the potential role of hypoxia in signaling pathway regulation. In the present study, we examined the impact of hypoxia on β-catenin status and the mechanisms involved. Hypoxia significantly decreased β-catenin protein, but had no effect on glycogen synthase kinase (GSK)-3β or adenomatous polyposis coli (APC) levels. However, hypoxia-induced β-catenin downregulation seemed to require APC but not GSK-3β. Further investigation revealed that hypoxia significantly upregulated Siah-1, the human homolog of Drosophila seven in absentia. In addition, hypoxia augmented the interaction between β-catenin and SIP and Skp1. Silencing of Siah-1, as well as the use of a dominant negative Siah-1 mutant, attenuated these responses to hypoxia and rescued β-catenin transactivation. The Siah-1-mediated degradation of β-catenin during hypoxia may involve p53, but not hypoxia-inducible factor-1, activation. Together, the results suggest that hypoxia downregulates β-catenin by increasing Siah-1 expression in a p53-dependent manner.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466614     DOI: 10.1111/j.1349-7006.2011.01950.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  9 in total

1.  Inhibition of WNT/β-catenin signaling under serum starvation and hypoxia induces adipocytic transdifferentiation in human leiomyoma cells.

Authors:  Hiroshi Harada; Yojiro Tsuda; Kei Yabuki; Eisuke Shiba; Kazuyoshi Uchihashi; Atsuji Matsuyama; Yoshihisa Fujino; Toru Hachisuga; Masanori Hisaoka
Journal:  Lab Invest       Date:  2018-01-18       Impact factor: 5.662

2.  Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.

Authors:  Donald J Scholten; Christine M Timmer; Jacqueline D Peacock; Dominic W Pelle; Bart O Williams; Matthew R Steensma
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

3.  The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer.

Authors:  Anna Chen; Christina S F Wong; Mira C P Liu; Colin M House; Jaclyn Sceneay; David D Bowtell; Erik W Thompson; Andreas Möller
Journal:  Oncotarget       Date:  2015-01-20

Review 4.  Crosstalk of Oncogenic Signaling Pathways during Epithelial-Mesenchymal Transition.

Authors:  Stephan Lindsey; Sigrid A Langhans
Journal:  Front Oncol       Date:  2014-12-11       Impact factor: 6.244

5.  Mitochondrial Dysfunction Due to Lack of Manganese Superoxide Dismutase Promotes Hepatocarcinogenesis.

Authors:  Anja Konzack; Mirza Jakupovic; Kateryna Kubaichuk; Agnes Görlach; Frank Dombrowski; Ilkka Miinalainen; Raija Sormunen; Thomas Kietzmann
Journal:  Antioxid Redox Signal       Date:  2015-11-05       Impact factor: 8.401

Review 6.  Direct phosphorylation events involved in HIF-α regulation: the role of GSK-3β.

Authors:  Daniela Mennerich; Elitsa Y Dimova; Thomas Kietzmann
Journal:  Hypoxia (Auckl)       Date:  2014-04-30

7.  Membrane-bound β-catenin degradation is enhanced by ETS2-mediated Siah1 induction in Helicobacter pylori-infected gastric cancer cells.

Authors:  L Das; S B Kokate; P Dixit; S Rath; N Rout; S P Singh; S E Crowe; A Bhattacharyya
Journal:  Oncogenesis       Date:  2017-05-08       Impact factor: 7.485

Review 8.  Ubiquitin Ligases Involved in the Regulation of Wnt, TGF-β, and Notch Signaling Pathways and Their Roles in Mouse Development and Homeostasis.

Authors:  Nikol Baloghova; Tomas Lidak; Lukas Cermak
Journal:  Genes (Basel)       Date:  2019-10-16       Impact factor: 4.096

Review 9.  Cross-Talk between p53 and Wnt Signaling in Cancer.

Authors:  Qiyun Xiao; Johannes Werner; Nachiyappan Venkatachalam; Kim E Boonekamp; Matthias P Ebert; Tianzuo Zhan
Journal:  Biomolecules       Date:  2022-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.